ABSTRACT

Introduction

Noninfectious uveitis represents one of the leading causes of blindness in developed Countries, compromising patients’ quality of life and social functioning. The main treatment goals are the control of ocular inflammation, to avert and treat sight-threatening complications, thus preserving and/or restoring visual function.

Areas covered

This manuscript deals with systemic therapy with biologic drugs for noninfectious uveitis. An extensive literature search in the MEDLINE database (via PubMed) has been performed up to June 2020. The major classes of biologic molecules employed in ocular inflammatory diseases have been reviewed, focusing on TNF inhibitors, IL-1, IL-6, IL-17, IL-23 inhibitors, interferons, rituximab, and abatacept efficacy and safety. An overview of most recent developments in the field has been provided as well, with reference to the experience with JAK inhibitors and with biosimilar drugs.

Expert opinion

The development of the concept of targeted therapy and the subsequent introduction of biologic molecules in clinical practice have revolutionized the prognosis of uveitis. The target of a rapid and sustained steroid-free remission of ocular inflammation should be pursued for all patients early in the disease course, in order to have a better chance to improve the final visual outcome.

中文翻译：

---

葡萄膜炎生物治疗的现状。

摘要

介绍

非感染性葡萄膜炎是发达国家失明的主要原因之一，影响患者的生活质量和社会功能。主要治疗目标是控制眼部炎症，避免和治疗威胁视力的并发症，从而保护和/或恢复视觉功能。

覆盖区域

这份手稿涉及使用生物药物治疗非感染性葡萄膜炎的全身治疗。已在 MEDLINE 数据库（通过 PubMed）中进行了广泛的文献检索，直至 2020 年 6 月。已经审查了眼部炎症性疾病中使用的主要生物分子类别，重点是 TNF 抑制剂、IL-1、IL-6、IL- 17、IL-23抑制剂、干扰素、利妥昔单抗和阿巴西普的疗效和安全性。还提供了该领域最新进展的概述，参考了 JAK 抑制剂和生物仿制药的经验。

专家意见

靶向治疗概念的发展以及随后在临床实践中引入生物分子已经彻底改变了葡萄膜炎的预后。所有患者都应在病程早期追求快速且持续的无类固醇缓解眼部炎症的目标，以便有更好的机会改善最终的视力结果。